Print

Orexo AB (ORXOF) Slumps on Affaersvaerlden Zubsolv Risks  
10/2/2013 7:56:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Orexo AB (ORX) fell the most in more than a year in Stockholm trading after the Affaersvaerlden business magazine said it sees risks for disappointment when the company presents sales data for its Zubsolv medication this month. The shares dropped as much as 8.8 percent to 114 kronor, their steepest intraday decline since Sept. 21 last year. The stock lost 8 percent to 115 kronor as of 11:44 a.m. local time, making it the biggest decliner among the 278 companies on the OMX Stockholm All-Share Index today.

Help employers find you! Check out all the jobs and post your resume.

//-->